Business Context and Reporting Period
This Form 8-K is filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on August 9, 2018. The report serves to announce the financial results for the quarter ended June 30, 2018. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release attached as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K form itself.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc., as the input metadata incorrectly listed Spyre Therapeutics, Inc.
- Locate and review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended June 30, 2018.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial data in this specific 8-K text is not incorporated by reference into other SEC filings.